StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
BofA/Merrill Lynch Downgrades Puma Biotechnology (PBYI) to Underperform
November 2, 2018 9:18 AM
BofA/Merrill Lynch analyst Ying Huang downgraded Puma Biotechnology (NASDAQ: PBYI) from Buy to ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst PT Change
Downgrades
Hot Downgrades
Next Articles
JPMorgan Downgrades Puma Biotechnology (PBYI) to Underweight
November 2, 2018 5:55 AM
Barclays Downgrades Puma Biotechnology (PBYI) to Underweight
November 2, 2018 4:32 AM
Puma Biotech (PBYI) Reports Q3 EPS of $0.17
November 1, 2018 4:17 PM